BSE Live
Mar 27, 16:01Prev. Close
38.10
Open Price
38.86
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Mar 27, 15:16Prev. Close
38.09
Open Price
0.00
Bid Price (Qty.)
41.30 (35)
Offer Price (Qty.)
0.00 (0)
| Key Financial Ratios of Take Solutions (in Rs. Cr.) | Mar 20 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | |
| Per Share Ratios | ||||||
| Basic EPS (Rs.) | 1.69 | 1.18 | 1.14 | 1.44 | 1.52 | |
| Diluted EPS (Rs.) | 1.69 | 1.17 | 1.14 | 1.43 | 1.50 | |
| Cash EPS (Rs.) | 1.80 | 1.23 | 1.08 | 1.14 | 1.53 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | 52.93 | 51.54 | 52.02 | 38.88 | 26.55 | |
| Book Value [InclRevalReserve]/Share (Rs.) | 52.93 | 51.54 | 52.02 | 38.88 | 26.55 | |
| Dividend / Share(Rs.) | 0.00 | 1.00 | 1.60 | 1.00 | 1.00 | |
| Revenue from Operations/Share (Rs.) | 0.17 | 1.48 | 0.16 | 1.41 | 1.96 | |
| PBDIT/Share (Rs.) | 1.87 | 1.37 | 1.11 | 1.37 | 1.72 | |
| PBIT/Share (Rs.) | 1.75 | 1.32 | 1.05 | 1.31 | 1.70 | |
| PBT/Share (Rs.) | 1.72 | 1.32 | 1.00 | 1.09 | 1.69 | |
| Net Profit/Share (Rs.) | 1.69 | 1.18 | 1.03 | 1.08 | 1.52 | |
| Profitability Ratios | ||||||
| PBDIT Margin (%) | 1,122.18 | 92.49 | 671.69 | 97.09 | 87.55 | |
| PBIT Margin (%) | 1,051.54 | 88.84 | 638.96 | 92.86 | 86.76 | |
| PBT Margin (%) | 1,034.30 | 88.84 | 604.75 | 77.35 | 85.95 | |
| Net Profit Margin (%) | 1,011.27 | 79.21 | 625.59 | 76.53 | 77.33 | |
| Return on Networth / Equity (%) | 3.18 | 2.28 | 1.98 | 2.78 | 5.71 | |
| Return on Capital Employed (%) | 3.28 | 2.55 | 1.97 | 2.78 | 5.71 | |
| Return on Assets (%) | 3.14 | 2.24 | 1.96 | 2.70 | 4.40 | |
| Total Debt/Equity (X) | 0.00 | 0.00 | 0.00 | 0.00 | 0.23 | |
| Asset Turnover Ratio (%) | 0.31 | 2.83 | 0.31 | 3.52 | 5.69 | |
| Liquidity Ratios | ||||||
| Current Ratio (X) | 58.40 | 23.43 | 64.05 | 9.11 | 0.76 | |
| Quick Ratio (X) | 58.40 | 23.43 | 64.02 | 9.11 | 0.76 | |
| Inventory Turnover Ratio (X) | 98.64 | 686.22 | 13.18 | 785.13 | 481.02 | |
| Dividend Payout Ratio (NP) (%) | 23.72 | 136.06 | 87.35 | 92.38 | 67.14 | |
| Dividend Payout Ratio (CP) (%) | 22.17 | 130.07 | 83.01 | 87.55 | 66.46 | |
| Earnings Retention Ratio (%) | 76.28 | -36.06 | 12.65 | 7.62 | 32.86 | |
| Cash Earnings Retention Ratio (%) | 77.83 | -30.07 | 16.99 | 12.45 | 33.54 | |
| Valuation Ratios | ||||||
| Enterprise Value (Cr.) | 586.24 | 2,190.32 | 2,265.59 | 1,662.66 | 1,757.23 | |
| EV/Net Operating Revenue (X) | 237.73 | 99.75 | 929.28 | 88.24 | 74.55 | |
| EV/EBITDA (X) | 21.18 | 107.84 | 138.35 | 90.88 | 85.15 | |
| MarketCap/Net Operating Revenue (X) | 238.15 | 100.88 | 991.76 | 89.55 | 72.50 | |
| Retention Ratios (%) | 76.27 | -36.06 | 12.64 | 7.61 | 32.85 | |
| Price/BV (X) | 0.75 | 2.91 | 3.14 | 3.26 | 5.36 | |
| Price/Net Operating Revenue | 238.15 | 100.88 | 991.81 | 89.56 | 72.51 | |
| Earnings Yield | 0.04 | 0.01 | 0.01 | 0.01 | 0.01 |
01.01.2026
14.06.2024
Take Solutions Consolidated March 2024 Net Sales at Rs 13.21 crore, down 64.82% Y-o-Y
22.02.2024
Take Solutions Consolidated December 2023 Net Sales at Rs 16.85 crore, down 68.56% Y-o-Y
09.11.2023
Take Solutions Consolidated September 2023 Net Sales at Rs 18.09 crore, down 59.69% Y-o-Y
14.06.2024
Take Solutions Consolidated March 2024 Net Sales at Rs 13.21 crore, down 64.82% Y-o-Y
22.02.2024
Take Solutions Consolidated December 2023 Net Sales at Rs 16.85 crore, down 68.56% Y-o-Y
09.11.2023
Take Solutions Consolidated September 2023 Net Sales at Rs 18.09 crore, down 59.69% Y-o-Y
16.08.2023
Take Solutions Standalone June 2023 Net Sales at Rs 5.42 crore, down 59.51% Y-o-Y
27.03.2026
After Biologics merger, new CEO Shreehas Tambe recasts Biocon as global medicines player
27.03.2026
27.03.2026
26.03.2026
As Strides Pharma stabilises balance sheet, focus shifts to growth beyond the US
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth